Adagene Inc., a clinical-stage biotechnology company, has announced the launch of a Phase 1 clinical trial to explore a new combination therapy for patients with metastatic colorectal cancer. This trial, conducted in collaboration with City of Hope, seeks to provide innovative treatment options for patients whose cancer has resisted standard therapies.

Colorectal cancer is a significant health concern, being the second deadliest cancer in the United States. The urgency for new treatment options is underscored by the fact that approximately 159,000 Americans are diagnosed with colorectal cancer annually, with about 55,230 expected to die from the disease this year alone.

Background

Adagene Inc. operates within the pharmaceutical preparations sector (SIC: 2834) and is publicly traded on the Nasdaq under the ticker ADAG. The company focuses on transforming the discovery and development of novel antibody-based therapies. Its recent filings include a Form 6-K on November 17, 2026, detailing this latest clinical trial initiative.

What the Filing Says

The filing indicates that the trial will enroll up to 36 patients to evaluate the effectiveness of two experimental drugs, ivonescimab and muzastotug (ADG126), in treating advanced microsatellite stable colorectal cancer. Principal investigator Dr. Marwan G. Fakih emphasized the need for new treatment options, stating, "Colorectal cancer is the second deadliest cancer in the U.S., and current treatments don’t work for everyone. We urgently need to find new options, especially for the advanced stages of this challenging disease."

Impact

This trial may significantly affect patients suffering from metastatic colorectal cancer, particularly those who have not responded to existing treatments. The collaboration with City of Hope, a leading cancer research and treatment organization, enhances the credibility and potential impact of the trial results.

What's Next

Details were not available in the SEC filing regarding the next steps following this announcement.